Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandrine Roux

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
BMC Infectious Diseases|February 19, 2016
Daptomycin > 6 mg/kg/day as salvage therapy in patients with complex bone and joint infection: cohort study in a regional reference centerSandrine Roux, Florent Valour, Judith Karsenty, et al.
Annales Pharmaceutiques Francaises|October 25, 2024
Isavuconazole off-label use as an empirical treatment of invasive fungal infectionsAnne-Lise Bienvenu, Chloe Gasser, Sophie Ducastelle-Lepretre, et al.
Open Forum Infectious Diseases|August 2, 2021
Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort StudyTristan Ferry, Anne Conrad, Eric Senneville, et al.
The Journal of Antimicrobial Chemotherapy|January 11, 2019
Genetic polymorphisms of ABCB1 (P-glycoprotein) as a covariate influencing daptomycin pharmacokinetics: a population analysis in patients with bone and joint infectionRomain Bricca, Sylvain Goutelle, Sandrine Roux, et al.
Antimicrobial Agents and Chemotherapy|September 26, 2024
Parametric and nonparametric population pharmacokinetic analysis of fluconazole in critically ill patients and dosing simulations for <i>Candida</i> infectionsElodie Matusik, Olivia Vassal, Anne Conrad, et al.
Frontiers in Medicine|November 16, 2020
<i>Pseudomonas aeruginosa</i> Implant-Associated Bone and Joint Infections: Experience in a Regional Reference Center in FranceMatteo Cerioli, Cécile Batailler, Anne Conrad, et al.
Infectious Diseases Now|April 6, 2026
Efficacy and safety of dalbavancin as suppressive therapy in chronic implant-associated infectionsTomaso Beringheli, Céline Dupieux, Sylvain Goutelle, et al.
The Journal of Antimicrobial Chemotherapy|August 26, 2025
Peripheral neuropathy during long-term suppressive therapy with tedizolid: a case seriesTomaso Beringheli, Clément Javaux, Sandrine Roux, et al.
BMC Infectious Diseases|December 15, 2018
A retrospective study of factors associated with treatment decision for nontuberculous mycobacterial lung disease in adults without altered systemic immunityJudith Provoost, Florent Valour, Delphine Gamondes, et al.
The Journal of Antimicrobial Chemotherapy|June 13, 2022
Necrotizing external otitis: analysis of relapse risk factors in 66 patients managed during a 12 year periodWilliam Danjou, Paul Chabert, Thomas Perpoint, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
BMC Infectious Diseases|February 19, 2016
Daptomycin > 6 mg/kg/day as salvage therapy in patients with complex bone and joint infection: cohort study in a regional reference centerSandrine Roux, Florent Valour, Judith Karsenty, et al.
Annales Pharmaceutiques Francaises|October 25, 2024
Isavuconazole off-label use as an empirical treatment of invasive fungal infectionsAnne-Lise Bienvenu, Chloe Gasser, Sophie Ducastelle-Lepretre, et al.
Open Forum Infectious Diseases|August 2, 2021
Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort StudyTristan Ferry, Anne Conrad, Eric Senneville, et al.
The Journal of Antimicrobial Chemotherapy|January 11, 2019
Genetic polymorphisms of ABCB1 (P-glycoprotein) as a covariate influencing daptomycin pharmacokinetics: a population analysis in patients with bone and joint infectionRomain Bricca, Sylvain Goutelle, Sandrine Roux, et al.
Antimicrobial Agents and Chemotherapy|September 26, 2024
Parametric and nonparametric population pharmacokinetic analysis of fluconazole in critically ill patients and dosing simulations for <i>Candida</i> infectionsElodie Matusik, Olivia Vassal, Anne Conrad, et al.
Frontiers in Medicine|November 16, 2020
<i>Pseudomonas aeruginosa</i> Implant-Associated Bone and Joint Infections: Experience in a Regional Reference Center in FranceMatteo Cerioli, Cécile Batailler, Anne Conrad, et al.
Infectious Diseases Now|April 6, 2026
Efficacy and safety of dalbavancin as suppressive therapy in chronic implant-associated infectionsTomaso Beringheli, Céline Dupieux, Sylvain Goutelle, et al.
The Journal of Antimicrobial Chemotherapy|August 26, 2025
Peripheral neuropathy during long-term suppressive therapy with tedizolid: a case seriesTomaso Beringheli, Clément Javaux, Sandrine Roux, et al.
BMC Infectious Diseases|December 15, 2018
A retrospective study of factors associated with treatment decision for nontuberculous mycobacterial lung disease in adults without altered systemic immunityJudith Provoost, Florent Valour, Delphine Gamondes, et al.
The Journal of Antimicrobial Chemotherapy|June 13, 2022
Necrotizing external otitis: analysis of relapse risk factors in 66 patients managed during a 12 year periodWilliam Danjou, Paul Chabert, Thomas Perpoint, et al.
Pageof 3